Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 62

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 62
---
.00005 nominal value and 19 C Deferred Shares of £0.00005 nominal value each.

On January 17, 2025, we entered into a securities purchase agreement, or ELOC, with newly formed C/M Capital Master Fund LP, orthe
Investor, pursuant to which we, subject to the restrictions and satisfaction of the conditions in the ELOC, have the right, but not the obligation, to sell tothe Investor, andthe
Investor is obligated to purchase, up to $35.0 million of newly issued Depositary Shares over a 36-month period, unless the ELOC is terminated in accordance with its terms. As of the date of this prospectus, we have sold 51,468,000,000 Ordinary Shares under the ELOC, for gross proceeds of approximately $8.6 million, andissued 1,794,060,000 Ordinary Shares to the
Investor in satisfaction of a commitment fee.

On May 15, 2025, we entered
into the 2025 Warrant Agreements with certain Holders of our outstanding Series E Warrants, Series H Warrants, Series J Warrants, and
Series K Warrants issued in prior transactions, pursuant to which the Holders agreed to exercise certain of such warrants in exchange
for a reduction in exercise price of each warrant to $3.10 per share. An aggregate of 20,041 warrants were exercised for aggregate gross
proceeds of approximately $62,000, before estimate offering expenses.

Since their respective dates
of issuance, we have issued 1,529,030,000 Ordinary Shares upon exercises of the Series H Warrants, Series J Warrants and Series K Warrants,
including warrants exercised pursuant to the terms of the Warrant Agreements (other than shares held in abeyance).

On June 11, 2025, we held
the June 2025 GM and our shareholders passed resolutions to, among other things, subdivide our Ordinary Shares of £0.00005 nominal
value each into one Ordinary Share of £0.000001 nominal value and 49 D Deferred Shares of £0.000001 nominal value each.

On July 31, 2025, we effected
a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 10,000 Ordinary Shares per Depositary Share
to 100,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

Options

We have established the